10-Q: AppYea Inc. Reports First Quarter 2024 Results, Cites Ongoing Development and Commercialization Efforts

AppYea Inc. reported its financial results for the first quarter of 2024, highlighting initial product sales and continued investment in research and development.

Summary

• AppYea Inc. released its unaudited financial results for the quarter ended March 31, 2024, showing a net loss of $1.244 million, compared to a net loss of $289,000 for the same period in 2023.
• The company generated $13,000 in revenue from product sales, specifically the AppySleep wristband, marking the beginning of commercialization efforts.
• Research and development expenses increased to $60,000, up from $9,000 in the prior year, reflecting ongoing product development.
• General and administrative expenses decreased to $294,000 from $427,000 in the same quarter of the previous year.
• The company's cash and cash equivalents stood at $373,000 as of March 31, 2024, compared to $222,000 at the end of 2023.
• AppYea has an accumulated deficit of $7.57 million and a stockholders deficiency of $3.153 million, raising concerns about its ability to continue as a going concern.
• The company is dependent on external financing and is actively seeking additional capital to fund its operations and development programs.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a going concern warning, and a material weakness in internal controls, which overshadow the positive aspects of initial product sales and ongoing development efforts. The overall sentiment is negative due to the financial instability and operational risks.

Positives

• The company generated its first revenue of $13,000 from product sales, marking a significant step towards commercialization.
• Cash and cash equivalents increased to $373,000, providing some financial flexibility.
• The company is actively pursuing FDA approvals for its products, indicating a path towards market expansion.
• The company has established a logistical distribution facility in the US.

Negatives

• The company reported a substantial net loss of $1.244 million for the quarter, significantly higher than the previous year.
• AppYea has a significant accumulated deficit of $7.57 million and a stockholders deficiency of $3.153 million.
• The company's current liabilities exceed its current assets, indicating a working capital deficit of $3.407 million.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company is heavily reliant on external financing and may face challenges in securing adequate capital.
• The company has identified a material weakness in its internal controls related to segregation of duties.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and limited operations.
• The company is dependent on external financing, and there is no assurance that it will be able to raise sufficient capital.
• The company's products are still in development, and there is no guarantee of successful FDA approval or commercialization.
• The company faces competition in the anti-snoring and sleep apnea market.
• The company is involved in a legal proceeding that could have a material adverse effect on its business.
• The company has a material weakness in its internal controls over financial reporting.

Future Outlook

The company plans to file a 510(k) FDA submission for the AppySleep LAB app in 2024 and an FDA process for AppySleep PRO in 2026. The company aims to establish its technology as the gold standard in its targeted sectors over the next five years.

Management Comments

• Management believes that funds on hand will enable the company to fund operations through the end of the third quarter of 2024.
• Management acknowledges the need to raise additional operating capital to maintain operations and realize the business plan.
• Management is actively seeking additional capital through debt and equity securities.

Industry Context

The company operates in the growing market for anti-snoring and sleep apnea solutions, which is expected to reach $8.6 billion by 2028. The company's focus on AI-based wearable technology aligns with the trend towards at-home healthcare solutions.

Comparison to Industry Standards

• The company's revenue of $13,000 is very low compared to established medical device companies, which often report millions or billions in quarterly revenue.
• The company's net loss of $1.244 million is significant for a company of its size and stage, indicating a need for substantial revenue growth or cost reductions.
• The company's cash position of $373,000 is low compared to industry standards, where companies often have several million in cash reserves.
• The company's reliance on external financing is common for early-stage medical device companies, but the level of dependence and the going concern warning are concerning.
• The company's focus on AI-based wearable technology is in line with industry trends, but the company needs to demonstrate its technology's effectiveness and market acceptance.

Management Changes

Legal Proceedings

• A lawsuit was filed in the Tel Aviv Magistrates Court against the company's Chairman and other related parties, alleging breach of partnership and loan agreements.
• The lawsuit has been transferred to the economic department of the District Court in Tel Aviv.
• The parties are considering mediation to resolve the dispute.

Related Party Transactions

• SleepX borrowed from Nexense Technologies USA. Inc., a company majority owned by the company's Chairman.
• The minority shareholder of Ta-nooma advanced a loan to Ta-nooma.
• The company has related party payables and short-term loans from related parties.
• The company's Chairman and CFO do not receive compensation for their directorship roles.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and going concern warning.
• Employees may be affected by potential cost reduction measures or delays in development programs.
• Customers may be impacted by potential delays in product development or commercialization.
• Creditors face risks due to the company's high level of liabilities and uncertain financial future.

Next Steps

• The company plans to file a 510(k) FDA submission for the AppySleep LAB app in 2024.
• The company plans to pursue an FDA process for AppySleep PRO in 2026.
• The company intends to continue to finance its operating activities by raising capital.
• The company will attempt mediation in the ongoing legal proceedings.

Key Dates

Keywords

sleep apnea, snoring, wearable technology, biofeedback, FDA approval, medical devices, digital health, financial results, research and development, AppySleep